Loading...
Loading...
ACADIA Pharmaceuticals
, a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today announced the
completion of enrollment in its ongoing pivotal Phase III trial with
pimavanserin in patients with Parkinson's disease psychosis (PDP). Top-line
results from this trial are expected to be announced by the end of November
2012.
The Phase III trial, referred to as the -020 Study, is a multi-center,
double-blind, placebo-controlled study designed to evaluate the efficacy,
tolerability and safety of pimavanserin as a treatment for patients with PDP.
The -020 Study incorporates several design enhancements that were guided by
previous data in ACADIA's PDP program. A total of 198 patients have been
enrolled in the study and were randomized on a one-to-one basis to receive
either 40 mg of pimavanserin or placebo once-daily for six weeks. The primary
endpoint of the -020 Study is antipsychotic efficacy as measured using nine
items from the hallucinations and delusions domains of the Scale for the
Assessment of Positive Symptoms, or SAPS. An independent group of centralized
raters is used to assess the primary endpoint in the study. Motoric
tolerability is a key secondary endpoint in the study and is measured using
Parts II and III of the Unified Parkinson's Disease Rating Scale, or UPDRS.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in